|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claim-Strength Analysis: US 10,577,154 (SiOx Barrier + SiOxCy Passivation on Thermoplastic Medical Vessels)
US 10,577,154 claims a medical “vessel” (including syringe barrel, cartridge, vial, blister) with a specific dual-layer silicon-oxide coating stack: a PECVD-deposited SiOₓ barrier (x = 1.5 to 2.9) and a PECVD SiOₓCᵧ passivation layer (x = 0.5 to 2.4, y = 0.6 to 3) positioned in a defined order between the fluid and thermoplastic interior surface. The core novelty posture is that the passivation layer preserves the barrier’s performance against dissolution/erosion and controls silicon dissolution to low levels while maintaining barrier improvement for at least six months. The claims also hard-wire multiple performance metrics (six-month barrier improvement durability, erosion rate comparisons, nm-per-contact-time removal limits, silicon dissolution in a specified buffer with polysorbate-80 at pH 8, and shelf-life windows). The broadest “tie-down” is that PECVD process parameters are recited only as deposition method, while performance is tied to measurable outcomes.
What does US 10,577,154 actually claim, in functional terms?
Claim 1 is the independent claim and includes the following required elements (all must be met):
Structural and materials limitations (vessel + wall + internal coatings)
- A vessel with a thermoplastic wall having:
- Interior surface enclosing a lumen
- A fluid contained in the lumen with pH > 5
- A barrier coating/layer:
- Material: SiOₓ, where x = 1.5 to 2.9
- Deposition method: PECVD
- Location/order: between the thermoplastic interior surface and the fluid
- Durability behavior: the barrier layer is measurably diminished in barrier improvement factor in less than six months as a result of attack by the fluid
- A passivation layer/pH protective coating:
- Material: SiOₓCᵧ, where:
- x = 0.5 to 2.4
- y = 0.6 to 3
- Deposition method: PECVD
- Location/order: between the barrier layer and the fluid
- Performance behavior: effective to keep the barrier layer at least substantially undissolved as a result of fluid attack for at least six months
Drug and package-type scope (claims 9 and 3)
- Claim 3: the vessel comprises syringe barrel, cartridge, vial, or blister package
- Claim 9: fluid comprises a drug
Fluid pH scope (claim 4)
- Claim 4: fluid composition has pH up to 9
How hard are the performance metrics, and what do they imply for infringement risk?
Claims 5 through 8 add “gates” that constrain candidate designs to those that meet quantified coating-attack performance. The metrics are test-condition heavy and therefore create both (i) strong validity posture if the inventors can prove unexpected results, and (ii) a path for design-around if competitors can alter dissolution behavior or choose different oxide chemistry/stack architecture.
Quantified performance requirements
| Claim |
Test/metric requirement |
Key constraint |
| 5 |
With fluid at pH 8, erosion rate of passivation layer < 20% of erosion rate of barrier layer (under same conditions) |
Passivation must be much more erosion-resistant than barrier in matched conditions |
| 6 |
Fluid removes passivation layer at ≤ 1 nm per 44 hours contact |
Passivation removal must be extremely slow in direct contact |
| 7 |
Silicon dissolution rate from vessel into 50 mM potassium phosphate buffer diluted in water for injection, pH adjusted to 8 with concentrated nitric acid, containing 0.2 wt.% polysorbate-80: < 170 ppb/day |
Direct cap on Si dissolution in a harsh surfactant-containing buffer |
| 8 |
Calculated shelf life (total Si / Si dissolution rate) is > 1 year and < 5 years |
Forces a mid-range shelf-life window, not indefinite durability |
Critical internal tension inside Claim 1
Claim 1 contains a durability split that is internally directional but can become an interpretive vulnerability:
- The barrier coating is stated to be “subject to being measurably diminished in barrier improvement factor in less than six months” due to fluid attack.
- Yet the passivation layer is stated to keep the barrier “at least substantially undissolved … for a period of at least six months.”
In practice, “barrier improvement factor” (a composite barrier-property metric) and “undissolved” (silicon dissolution/structural integrity) can differ. But this language increases the chance that:
- Accused products must show both: barrier property diminishes earlier, while dissolution remains suppressed for at least six months; or
- The court construes “measurably diminished” as a dissolution-related decline, which would conflict with “substantially undissolved for at least six months.”
That internal bifurcation is a litigation pressure point.
How likely is the claim set to be attacked on novelty/obviousness?
The claim’s novelty posture rests on a specific combination:
- dual-layer PECVD silicon oxide stack (SiOₓ barrier + SiOₓCᵧ passivation),
- defined composition ranges (x and y windows),
- defined ordering (thermoplastic → SiOₓ barrier → SiOₓCᵧ passivation → fluid),
- and quantified durability/dissolution outcomes (including the stringent Si dissolution test in pH 8 buffer + polysorbate-80).
This structure is likely positioned against prior art covering:
- silicon oxide barrier coatings for medical containers,
- carbon-containing oxide or “SiOxCy” variants for improved chemical resistance,
- PECVD coating processes,
- and general barrier/dissolution testing.
Likely weak spots
- Overbreadth via ranges and functional language
- Composition ranges are wide (x and y each have substantial span). Without narrow “must-use” PECVD process conditions, competitors may argue their coatings fall outside the windows or do not achieve the claimed performance gates.
- Outcome-determined claim limitations
- Claims 5 to 8 depend on quantified test outcomes. If prior art reports similar test outcomes for different stacks or uses different coating materials with overlapping composition ranges, obviousness becomes available.
- The “less than six months” barrier improvement clause
- If prior art shows consistent barrier performance for longer than six months, that particular phrase can become a distinguishing artifact rather than a true technical limitation. Examiners can still treat it as limiting, but it is a claim-construction risk zone.
- Claim 10 (not provided) is absent
- The user input includes claims 1-13 but not the patent header metadata. Without dependent claim text beyond 13, the landscape assessment is constrained to what was supplied.
Likely strong spots
- Specific silicon dissolution test prescription
- Claim 7’s test matrix (50 mM potassium phosphate buffer, pH 8, polysorbate-80 at 0.2 wt.% and nitric acid adjustment) is a specific stress model. Prior art must match these conditions to anticipate or render the limitation obvious.
- Erosion rate differential and nm-per-contact removal
- Claim 5 and claim 6 add kinetic constraints that are difficult to match accidentally.
- Shelf life window is constrained
- Claim 8 restricts calculated shelf life to between 1 and 5 years. Prior art claiming “>5 years” or “indefinite barrier” may not read cleanly on the numeric range (though obviousness can still be argued if the prior art teaches the same approach).
Where does this patent sit in the broader coating/barrier technology landscape?
The claim set aligns with a category of medical packaging innovations that target:
- moisture/oxygen permeability reduction (barrier layer),
- chemical attack resistance under non-neutral pH and surfactants (passivation),
- and extractables control (silicon dissolution).
The use of PECVD is consistent with a mainstream manufacturing route for thin, conformal inorganic barrier films on polymeric substrates. The differentiation is in the duplex chemistry:
- barrier: SiOₓ
- passivation: SiOₓCᵧ
This indicates a designed response to fluid-driven silicon release and/or dissolution kinetics.
What is the effective claim “coverage envelope,” claim-by-claim?
Claim 1: the coverage envelope
- Thermoplastic container with lumen.
- Fluid pH > 5 (and later claims extend up to 9).
- Requires the exact coating architecture and compositions within specified ranges.
- Requires the passivation to preserve barrier undissolvedness for at least six months.
- Requires barrier property deterioration “in less than six months” as a result of fluid attack (a dual requirement).
Coverage risk profile: Medium to high for design-around if competitors can:
- change coating composition (outside x or y windows),
- avoid SiOₓCᵧ as the passivation (use different passivation chemistry),
- use non-PECVD deposition (if “applied by PECVD” is treated as limiting to the actual manufacturing method),
- or fail the specific quantitative gates in claims 5-8.
Claims 2-4: narrowing material and pH
- Claim 2 narrows wall materials to listed thermoplastics (polyolefin, cyclic olefin polymer/copolymer, polyester, polycarbonate, polylactic acid, etc.).
- Claim 4 caps fluid pH at 9.
Coverage risk profile: Low risk if the accused vessels use those polymer categories and are intended for near-neutral to mildly basic formulations.
Claims 5-8: performance gates (most litigated)
These are the most enforceable limitations because they require quantified behaviors under controlled conditions.
Coverage risk profile: High for infringement unless coating stacks are tested to meet these outcomes.
Claim 3: specific package types
Syringe barrel, cartridge, vial, blister package.
Coverage risk profile: Medium. Many polymeric medical containers fall into these categories; exclusion depends on vessel type definitions.
Claim 9: fluid includes a drug
Nearly all relevant medical uses.
Coverage risk profile: Low.
Claims 11-13: shelf life minimum and caps (two layered shelf-life limits)
- Claim 11: minimum shelf life at least two years post assembly.
- Claim 12: shelf life up to ten years.
- Claim 13: shelf life determined at 20°C.
Coverage risk profile: Medium. These constraints conflict with the earlier claim 8 numeric shelf-life window of >1 and <5 years unless claim interpretation treats “calculated shelf life” differently from “shelf life after assembly.” The claim set can still be internally consistent if “calculated shelf life” differs from “determined shelf life,” but it increases claim-construction complexity.
What is the likely patent landscape strategy for competitors?
Given the claim dependence on:
- coating chemistry ranges (SiOₓ, SiOₓCᵧ),
- deposition method (PECVD),
- and quantified performance gates (erosion and Si dissolution),
competitors have several typical strategy vectors:
-
Change passivation chemistry
Use a different passivating layer (non SiOₓCᵧ) or a different carbon incorporation approach that keeps barrier dissolution down without meeting the SiOₓCᵧ definition (x and y windows).
-
Modify stack architecture
The claim order is fixed: barrier directly supports by thermoplastic, passivation between barrier and fluid. If competitors insert additional layers or change sequencing, literal infringement risk drops, though doctrine-of-equivalents risk can remain.
-
Use alternative deposition
If PECVD is a strict limiting phrase, switching to ALD, sputtering, sol-gel, or thermal oxidation routes can be a clean design-around if the claim construction treats “applied by PECVD” as mandatory.
-
Target failure of numerical gates
Competing coatings can be engineered to increase erosion of passivation or silicon dissolution just enough to exceed the numeric thresholds. That can be commercially viable if the product’s stability requirements allow it, but it is a straightforward legal lever.
-
Exploit the internal “barrier improvement factor” vs “undissolved” distinction
If competitors can demonstrate that barrier improvement factor declines faster but silicon dissolution remains outside or vice versa, they can attempt to defeat the dual durability requirement depending on claim construction.
Key Takeaways
- US 10,577,154 is a thin-film medical packaging patent centered on a PECVD dual-layer silicon coating stack: SiOₓ (x 1.5-2.9) barrier and SiOₓCᵧ (x 0.5-2.4, y 0.6-3) passivation, with specific ordering between thermoplastic and fluid.
- The enforceability hinges on quantified performance outcomes: erosion differential (<20%), passivation removal (≤1 nm per 44 hours), silicon dissolution cap (<170 ppb/day in a defined pH 8 buffer with 0.2 wt.% polysorbate-80), and a calculated shelf-life range (1 to 5 years).
- Several claim elements create litigation leverage: the “barrier improvement factor diminishes in <6 months” clause juxtaposed with “barrier substantially undissolved for at least six months,” and the layered shelf-life constraints that may require careful claim construction.
- For competitors, the most practical design-arounds are to change passivation chemistry, stack ordering/architecture, deposition method away from PECVD, or to miss the numerical erosion/silicon dissolution gates.
FAQs
-
What is the passivation layer chemistry required by US 10,577,154?
The passivation layer is SiOₓCᵧ deposited by PECVD, with x between 0.5 and 2.4 and y between 0.6 and 3.
-
What test condition anchors the silicon dissolution limitation?
Claim 7 specifies dissolution into 50 mM potassium phosphate buffer diluted in water for injection, pH 8 (adjusted with concentrated nitric acid), containing 0.2 wt.% polysorbate-80, requiring <170 ppb/day silicon dissolution.
-
Does the patent cover only acidic fluids?
No. Claim 1 requires pH > 5, and claim 4 extends coverage to fluids with pH up to 9.
-
Which vessel formats are explicitly covered?
Claim 3 explicitly includes syringe barrels, cartridges, vials, and blister packages.
-
Where is infringement most likely to be decided in litigation?
On the numeric performance limits in claims 5-8 (erosion differential, nm removal rate, ppb/day silicon dissolution, and calculated shelf-life range), plus whether the accused coatings match the claimed PECVD dual-layer chemistry and ordering.
References (APA)
- United States Patent. US 10,577,154. (Patent claims excerpt provided in prompt).
More… ↓
⤷ Start Trial
|
